Eton Pharmaceuticals, Inc announced that it has entered into a multi-year agreement with Tolmar Pharmaceuticals, Inc. to co-promote Alkindi Sprinkle.
Eton Pharmaceuticals, Inc announced that the FDA has approved Alkindi Sprinkle (hydrocortisone) oral granules as replacement therapy for Adrenocortical Insufficiency (AI) in children under 17 years of age.
-Neurocrine Biosciences, Inc. announced the FDA has accepted its New Drug Application (NDA) for Ingrezza (valbenazine) oral granules, a new sprinkle formulation of Ingrezza (valbenazine) capsules for oral administration. The agency set a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2024